Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2014, Article ID 908636, 8 pages
http://dx.doi.org/10.1155/2014/908636
Review Article

Matrix Metalloproteinases and Their Multiple Roles in Alzheimer’s Disease

1Department of Neurology, Qingdao Municipal Hospital, School of Medicine, Qingdao University, No. 5 Donghai Middle Road, Qingdao 266071, China
2Department of Neurology, Qingdao Huangdao District People’s Hospital, Qingdao 266400, China
3Department of Neurology, Qingdao Municipal Hospital, College of Medicine and Pharmaceutics, Ocean University of China, Qingdao 266003, China

Received 9 February 2014; Revised 9 June 2014; Accepted 10 June 2014; Published 24 June 2014

Academic Editor: Raymond Chuen-Chung Chang

Copyright © 2014 Xiang-Xiang Wang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. I. M. Ethell and D. W. Ethell, “Matrix metalloproteinases in brain development and remodeling: Synaptic functions and targets,” Journal of Neuroscience Research, vol. 85, no. 13, pp. 2813–2823, 2007. View at Publisher · View at Google Scholar · View at Scopus
  2. B. Mroczko, M. Groblewska, and M. Barcikowska, “The role of matrix metalloproteinases and tissue inhibitors of metalloproteinases in the pathophysiology of neurodegeneration: a literature study,” Journal of Alzheimer's Disease, vol. 37, no. 2, pp. 273–283, 2013. View at Google Scholar
  3. M. Fujimoto, Y. Takagi, T. Aoki et al., “Tissue inhibitor of metalloproteinases protect blood-brain barrier disruption in focal cerebral ischemia,” Journal of Cerebral Blood Flow and Metabolism, vol. 28, no. 10, pp. 1674–1685, 2008. View at Publisher · View at Google Scholar · View at Scopus
  4. J. Haorah, S. H. Ramirez, K. Schall, D. Smith, R. Pandya, and Y. Persidsky, “Oxidative stress activates protein tyrosine kinase and matrix metalloproteinases leading to blood-brain barrier dysfunction,” Journal of Neurochemistry, vol. 101, no. 2, pp. 566–576, 2007. View at Publisher · View at Google Scholar · View at Scopus
  5. O. Sbai, L. Ferhat, A. Bernard et al., “Vesicular trafficking and secretion of matrix metalloproteinases-2, -9 and tissue inhibitor of metalloproteinases-1 in neuronal cells,” Molecular and Cellular Neuroscience, vol. 39, no. 4, pp. 549–568, 2008. View at Publisher · View at Google Scholar · View at Scopus
  6. S. Merlo and M. A. Sortino, “Estrogen activates matrix metalloproteinases-2 and -9 to increase beta amyloid degradation,” Molecular and Cellular Neuroscience, vol. 49, no. 4, pp. 423–429, 2012. View at Publisher · View at Google Scholar · View at Scopus
  7. J. S. Miners, S. Baig, J. Palmer, L. E. Palmer, P. G. Kehoe, and S. Love, “Aβ-degrading enzymes in Alzheimer's disease,” Brain Pathology, vol. 18, no. 2, pp. 240–252, 2008. View at Publisher · View at Google Scholar · View at Scopus
  8. W. Li, E. Poteet, L. Xie, R. Liu, Y. Wen, and S. Yang, “Regulation of matrix metalloproteinase 2 by oligomeric amyloid β protein,” Brain Research, vol. 1387, pp. 141–148, 2011. View at Publisher · View at Google Scholar · View at Scopus
  9. X.-H. Li, B.-L. Lv, J.-Z. Xie, J. Liu, X.-W. Zhou, and J. Wang, “AGEs induce Alzheimer-like tau pathology and memory deficit via RAGE-mediated GSK-3 activation,” Neurobiology of Aging, vol. 33, no. 7, pp. 1400–1410, 2012. View at Publisher · View at Google Scholar · View at Scopus
  10. H. J. Cho, S. M. Son, S. M. Jin et al., “RAGE regulates BACE1 and Aβ generation via NFAT1 activation in Alzheimer's disease animal model,” The FASEB Journal, vol. 23, no. 8, pp. 2639–2649, 2009. View at Publisher · View at Google Scholar · View at Scopus
  11. S. Kook, H. S. Hong, M. Moon, C. M. Ha, S. Chang, and I. Mook-Jung, “Aβ1-42-rage interaction disrupts tight junctions of the blood-brain barrier via Ca2+-calcineurin signaling,” Journal of Neuroscience, vol. 32, no. 26, pp. 8845–8854, 2012. View at Publisher · View at Google Scholar · View at Scopus
  12. H. Du, P. Li, J. Wang, X. Qing, and W. Li, “The interaction of amyloid b and the receptor for advanced glycation endproducts induces matrix metalloproteinase-2 expression in brain endothelial cells,” Cellular and Molecular Neurobiology, vol. 32, no. 1, pp. 141–147, 2012. View at Publisher · View at Google Scholar · View at Scopus
  13. C. Haass and D. J. Selkoe, “Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β-peptide,” Nature Reviews Molecular Cell Biology, vol. 8, no. 2, pp. 101–112, 2007. View at Publisher · View at Google Scholar · View at Scopus
  14. H. Hashimoto, T. Takeuchi, K. Komatsu, K. Miyazaki, M. Sato, and S. Higashi, “Structural basis for matrix metalloproteinase-2 (MMP-2)-selective inhibitory action of β-amyloid precursor protein-derived inhibitor,” The Journal of Biological Chemistry, vol. 286, no. 38, pp. 33236–33243, 2011. View at Publisher · View at Google Scholar · View at Scopus
  15. P. J. Crouch, D. J. Tew, T. Du et al., “Restored degradation of the Alzheimer's amyloid-β peptide by targeting amyloid formation,” Journal of Neurochemistry, vol. 108, no. 5, pp. 1198–1207, 2009. View at Publisher · View at Google Scholar · View at Scopus
  16. H. Mizoguchi, K. Takuma, E. Fukuzaki et al., “Matrix metalloprotease-9 inhibition improves amyloid β-mediated cognitive impairment and neurotoxicity in mice,” Journal of Pharmacology and Experimental Therapeutics, vol. 331, no. 1, pp. 14–22, 2009. View at Publisher · View at Google Scholar · View at Scopus
  17. M. A. Bruno, E. J. Mufson, J. Wuu, and A. C. Cuello, “Increased matrix metalloproteinase 9 activity in mild cognitive impairment,” Journal of Neuropathology and Experimental Neurology, vol. 68, no. 12, pp. 1309–1318, 2009. View at Publisher · View at Google Scholar · View at Scopus
  18. S. Lorenzl, K. Buerger, H. Hampel, and M. F. Beal, “Profiles of matrix metalloproteinases and their inhibitors in plasma of patients with dementia,” International Psychogeriatrics, vol. 20, no. 1, pp. 67–76, 2008. View at Publisher · View at Google Scholar · View at Scopus
  19. M. Bjerke, H. Zetterberg, Å. Edman, K. Blennow, A. Wallin, and U. Andreasson, “Cerebrospinal fluid matrix metalloproteinases and tissue inhibitor of metalloproteinases in combination with subcortical and cortical biomarkers in vascular dementia and Alzheimer's disease,” Journal of Alzheimer's Disease, vol. 27, no. 3, pp. 665–676, 2011. View at Publisher · View at Google Scholar · View at Scopus
  20. A. A. Talamagas, S. Efthimiopoulos, E. C. Tsilibary, M. E. Figueiredo-Pereira, and A. K. Tzinia, “Abeta(1–40)-induced secretion of matrix metalloproteinase-9 results in sAPPα release by association with cell surface APP,” Neurobiology of Disease, vol. 28, no. 3, pp. 304–315, 2007. View at Publisher · View at Google Scholar · View at Scopus
  21. P. Michaluk, L. Mikasova, L. Groc, R. Frischknecht, D. Choquet, and L. Kaczmarek, “Matrix metalloproteinase-9 controls NMDA receptor surface diffusion through integrin β1 signaling,” Journal of Neuroscience, vol. 29, no. 18, pp. 6007–6012, 2009. View at Publisher · View at Google Scholar · View at Scopus
  22. S. Guo, S. Wang, W. J. Kim et al., “Effects of apoE isoforms on beta-amyloid-induced matrix metalloproteinase-9 in rat astrocytes,” Brain Research, vol. 1111, no. 1, pp. 222–226, 2006. View at Publisher · View at Google Scholar · View at Scopus
  23. R. D. Bell, E. A. Winkler, I. Singh et al., “Apolipoprotein e controls cerebrovascular integrity via cyclophilin A,” Nature, vol. 485, no. 7399, pp. 512–516, 2012. View at Publisher · View at Google Scholar · View at Scopus
  24. P. Yan, X. Hu, H. Song et al., “Matrix metalloproteinase-9 degrades amyloid-β fibrils in vitro and compact plaques in situ,” The Journal of Biological Chemistry, vol. 281, no. 34, pp. 24566–24574, 2006. View at Publisher · View at Google Scholar · View at Scopus
  25. C. Barkus, S. B. McHugh, R. Sprengel, P. H. Seeburg, J. N. P. Rawlins, and D. M. Bannerman, “Hippocampal NMDA receptors and anxiety: at the interface between cognition and emotion,” European Journal of Pharmacology, vol. 626, no. 1, pp. 49–56, 2010. View at Publisher · View at Google Scholar · View at Scopus
  26. M. Koronyo-Hamaoui, M. K. Ko, Y. Koronyo et al., “Attenuation of AD-like neuropathology by harnessing peripheral immune cells: local elevation of IL-10 and MMP-9,” Journal of Neurochemistry, vol. 111, no. 6, pp. 1409–1424, 2009. View at Publisher · View at Google Scholar · View at Scopus
  27. O. Clewes, M. S. Fahey, S. J. Tyler et al., “Human ProNGF: biological effects and binding profiles at TrkA, P75NTR and sortilin,” Journal of Neurochemistry, vol. 107, no. 4, pp. 1124–1135, 2008. View at Publisher · View at Google Scholar · View at Scopus
  28. C. Costantini, R. Weindruch, G. Della Valle, and L. Puglielli, “A TrkA-to-p75NTR molecular switch activates amyloid β-peptide generation during aging,” Biochemical Journal, vol. 391, part 1, pp. 59–67, 2005. View at Publisher · View at Google Scholar · View at Scopus
  29. B. Frost, R. L. Jacks, and M. I. Diamond, “Propagation of tau misfolding from the outside to the inside of a cell,” The Journal of Biological Chemistry, vol. 284, no. 19, pp. 12845–12852, 2009. View at Publisher · View at Google Scholar · View at Scopus
  30. M. Hernández-Guillamon, P. Delgado, L. Ortega et al., “Neuronal TIMP-1 release accompanies astrocytic MMP-9 secretion and enhances astrocyte proliferation induced by β-amyloid 25-35 fragment,” Journal of Neuroscience Research, vol. 87, no. 9, pp. 2115–2125, 2009. View at Publisher · View at Google Scholar · View at Scopus
  31. F. Mannello and V. Medda, “Nuclear localization of Matrix metalloproteinases,” Progress in Histochemistry and Cytochemistry, vol. 47, no. 1, pp. 27–58, 2012. View at Publisher · View at Google Scholar · View at Scopus
  32. G. Nübling, J. Levin, B. Bader et al., “Limited cleavage of tau with matrix-metalloproteinase MMP-9, but not MMP-3, enhances tau oligomer formation,” Experimental Neurology, vol. 237, no. 2, pp. 470–476, 2012. View at Publisher · View at Google Scholar · View at Scopus
  33. D. H. Choi, E. Kim, H. J. Son et al., “A novel intracellular role of matrix metalloproteinase-3 during apoptosis of dopaminergic cells,” Journal of Neurochemistry, vol. 106, no. 1, pp. 405–415, 2008. View at Publisher · View at Google Scholar · View at Scopus
  34. C. Reitz, F. J. A. van Rooij, H. D. Soares et al., “Matrix metalloproteinase 3 haplotypes and plasma amyloid beta levels: the Rotterdam study,” Neurobiology of Aging, vol. 31, no. 4, pp. 715–718, 2010. View at Publisher · View at Google Scholar · View at Scopus
  35. S. Horstmann, L. Budig, H. Gardner et al., “Matrix metalloproteinases in peripheral blood and cerebrospinal fluid in patients with Alzheimer's disease,” International Psychogeriatrics, vol. 22, no. 6, pp. 966–972, 2010. View at Publisher · View at Google Scholar · View at Scopus
  36. N. Mattsson, P. Insel, R. Nosheny et al., “Effects of cerebrospinal fluid proteins on brain atrophy rates in cognitively healthy older adults,” Neurobiology of Aging, vol. 35, no. 3, pp. 614–622, 2014. View at Google Scholar
  37. N. Helbecque, D. Cottel, X. Hermant, and P. Amouyel, “Impact of the matrix metalloproteinase MMP-3 on dementia,” Neurobiology of Aging, vol. 28, no. 8, pp. 1215–1220, 2007. View at Publisher · View at Google Scholar · View at Scopus
  38. S. Vasto, G. Candore, G. Duro, D. Lio, M. P. Grimaldi, and C. Caruso, “Alzheimer's disease and genetics of inflammation: a pharmacogenomic vision,” Pharmacogenomics, vol. 8, no. 12, pp. 1735–1745, 2007. View at Publisher · View at Google Scholar · View at Scopus
  39. S. Ito, K. Kimura, M. Haneda, Y. Ishida, M. Sawada, and K. Isobe, “Induction of matrix metalloproteinases (MMP3, MMP12 and MMP13) expression in the microglia by amyloid-β stimulation via the PI3K/Akt pathway,” Experimental Gerontology, vol. 42, no. 6, pp. 532–537, 2007. View at Publisher · View at Google Scholar · View at Scopus
  40. E. Stomrud, M. Björkqvist, S. Janciauskiene, L. Minthon, and O. Hansson, “Alterations of matrix metalloproteinases in the healthy elderly with increased risk of prodromal Alzheimer's disease,” Alzheimer's Research and Therapy, vol. 2, no. 3, article 20, 2010. View at Publisher · View at Google Scholar · View at Scopus
  41. M. Liao and W. E. van Nostrand, “Degradation of soluble and fibrillar amyloid β-protein by matrix metalloproteinase (MT1-MMP) in vitro,” Biochemistry, vol. 49, no. 6, pp. 1127–1136, 2010. View at Publisher · View at Google Scholar · View at Scopus
  42. S. Higashi and K. Miyazaki, “Identification of amino acid residues of the matrix metalloproteinase-2 essential for its selective inhibition by β-amyloid precursor protein-derived inhibitor,” The Journal of Biological Chemistry, vol. 283, no. 15, pp. 10068–10078, 2008. View at Publisher · View at Google Scholar · View at Scopus
  43. K. Brew and H. Nagase, “The tissue inhibitors of metalloproteinases (TIMPs): an ancient family with structural and functional diversity,” Biochimica et Biophysica Acta—Molecular Cell Research, vol. 1803, no. 1, pp. 55–71, 2010. View at Publisher · View at Google Scholar · View at Scopus
  44. M. Inspector, J. Aharon-Perez, L. Glass-Marmor, and A. Miller, “Matrix metalloproteinase-9, its tissue inhibitor (TIMP)-1 and CRP in Alzheimer's disease,” European Neurology, vol. 53, no. 3, pp. 155–157, 2005. View at Publisher · View at Google Scholar · View at Scopus
  45. P. Lewczuk, J. Popp, N. Lelental et al., “Cerebrospinal fluid soluble amyloid-β protein precursor as a potential novel biomarkers of Alzheimer's disease,” Journal of Alzheimer's Disease, vol. 28, no. 1, pp. 119–125, 2012. View at Publisher · View at Google Scholar · View at Scopus
  46. J. C. Adair, J. Charlie, J. E. Dencoff et al., “Measurement of gelatinase B (MMP-9) in the cerebrospinal fluid of patients with vascular dementia and Alzheimer disease,” Stroke, vol. 35, no. 6, pp. e159–e162, 2004. View at Publisher · View at Google Scholar · View at Scopus